C-11 Hydroxylase Deficiency Clinical Presentation

  • Author: Gabriel I Uwaifo, MBBS; Chief Editor: George T Griffing, MD   more...
 
Updated: Nov 16, 2011
 

History

  • Virilization
    • Classic 46,XX patients present at birth with some degree of masculinization of their external genitalia.
    • Classic 46,XY patients typically present at 2-4 years of age with signs and symptoms of androgen excess, including increased growth velocity, advanced bone age, pubic hair, increased penile length, and aggressive behavior.
    • Later in life, males may have poor spermatogenesis that may manifest as azoospermia, oligospermia, and subsequent infertility.
    • Nonclassic 11-beta-hydroxylase deficiency is more subtle and presents later in life. Adolescent or adult females may present with amenorrhea, oligomenorrhea, or hirsutism.
  • Hypertension[5]
    • Hypertension occurs in approximately two thirds of patients with the severe (classic) form of 11-beta-hydroxylase deficiency.
    • In these patients, hypertension often develops in the first few years of life. Because the blood pressure elevation is mild to moderate, comparing the blood pressures of patients to age-appropriate levels is vital.
    • Patients are usually asymptomatic.
    • Consequences of hypertension include left ventricular hypertrophy, retinopathy, cardiovascular accidents, and hypertensive nephrosclerosis.
    • Excess mineralocorticoids in patients can cause hypokalemia and metabolic alkalosis, which may present as muscle weakness and ileus.
    • Patients with mild (nonclassic) varieties of 11-beta-hydroxylase deficiency typically have normal blood pressure.
  • Salt wasting
    • Salt wasting is a rare, but distinct, presentation.
    • Patients present with hyperkalemia, hyponatremia, and hypovolemia.
    • The exact pathophysiology is unclear, but it may be precipitated by glucocorticoid therapy.
Next

Physical

  • Ambiguous genitalia in XX patients are the most distinctive finding on physical examination.
    • The genital examination findings of XX patients vary depending on the degree of virilization.
    • Findings can include clitoromegaly that can be severe enough to simulate a male penis, or partial to full labioscrotal fold fusion that can simulate a scrotum (in the absence of palpable testicles).
    • Despite virilized external genitalia, patients who are 46,XX have normal female internal genitalia. For this reason, fertility is possible, and these patients should be raised as girls.
  • In children, other signs of androgen excess include early puberty, pubic hair, axillary hair, adult body odor, and growth acceleration. Accelerated growth and early epiphysial fusion result in short stature as adults.
  • Adult women may have signs of virilization, including muscular body habitus and hirsutism.
  • Hyperpigmentation akin to that observed in Addison disease may occur due to the accompanying excess of ACTH. The hyperpigmentation may be more prominent at pressure points, around the areolae, the buccal mucosa or other mucous membranes, the scrotum, and scar tissue.
  • Clinical features of uncontrolled hypertension, such as S4, heart failure, elevated blood pressure, and hypertensive retinopathy, may be present.
  • In affected young boys (aged 2-5 y), the phallus may have a greater length and thickness than are appropriate for the patients' chronologic age; these youngsters may also demonstrate advanced development of pubic and axillary hair. However, the testicular size in these boys tends to be small and firm (generally less than 5 mL in volume) and more consistent in size to their chronologic age. Palpable testicular masses in affected boys should raise the possibility of coexisting adrenal rest tumors. Apart from the testicles, these lesions can also arise in retroperitoneal locations, where they generally are clinically asymptomatic and often are first found through routine radiologic imaging tests.[7]
Previous
Next

Causes

  • An autosomal recessive disease, 11-beta-hydroxylase deficiency results from mutations in the CYP11B1 gene.[2] Moroccan Jews almost always show the same mutation—arginine (Arg) 448 to histidine (His) R448H.[6]
  • Thus far, no consistent phenotype-genotype correlations have been made.[3]
Previous
 
 
Contributor Information and Disclosures
Author

Gabriel I Uwaifo, MBBS  Clinical and Research Attending, Assistant Professor of Medicine and Endocrinology, MedStar Clinical Research Center, MedStar Research Institute and Washington Hospital Center

Gabriel I Uwaifo, MBBS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, American Society of Hypertension, and Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Ghassem Pourmotabbed, MD†  Former Associate Professor, Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Tennessee School of Medicine and Health Science Center

Ghassem Pourmotabbed, MD† is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, and Endocrine Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS  Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Endocrinology, American College of Nutrition, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Informatics Association, American Society for Bone and Mineral Research, Endocrine Society, and International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Mark Cooper, MBBS, PhD, FRACP  Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Deborah P Merke, MD, Chief of Pediatric Services, Pediatric and Reproductive Endocrinology Branch, Warren Grant Magnuson Clinical Center; Clinical Investigator, National Institute of Child Health and Human Development, contributed to this article.

References
  1. Mornet E, Dupont J, Vitek A. Characterization of two genes encoding human steroid 11 beta- hydroxylase (P-450(11) beta). J Biol Chem. Dec 15 1989;264(35):20961-7. [Medline]. [Full Text].

  2. Joehrer K, Geley S, Strasser-Wozak EM. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet. Oct 1997;6(11):1829-34. [Medline]. [Full Text].

  3. Zhu YS, Cordero JJ, Can S, et al. Mutations in CYP11B1 gene: phenotype-genotype correlations. Am J Med Genet A. Oct 15 2003;122(3):193-200. [Medline].

  4. Pascoe L, Curnow KM, Slutsker L. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A. Jun 1 1992;89(11):4996-5000. [Medline]. [Full Text].

  5. Davies E, Mackenzie SM, Freel EM, et al. Altered corticosteroid biosynthesis in essential hypertension: a digenic phenomenon. Mol Cell Endocrinol. Sep 19 2008;[Medline].

  6. Rosler A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. Am J Med Genet. Apr 1 1992;42(6):827-34. [Medline].

  7. Storr HL, Barwick TD, Snodgrass GA, et al. Hyperplasia of adrenal rest tissue causing a retroperitoneal mass in a child with 11 beta-hydroxylase deficiency. Horm Res. 2003;60(2):99-102. [Medline].

  8. Peter M, Janzen N, Sander S, et al. A case of 11beta-hydroxylase deficiency detected in a newborn screening program by second-tier LC-MS/MS. Horm Res. 2008;69(4):253-6. [Medline].

  9. Carlson AD, Obeid JS, Kanellopoulou N. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol. Apr-Jun 1999;69(1-6):19-29. [Medline].

  10. Cerame BI, Newfield RS, Pascoe L, et al. Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. J Clin Endocrinol Metab. Sep 1999;84(9):3129-34. [Medline]. [Full Text].

  11. Rosler A, Leiberman E, Rosenmann A, et al. Prenatal diagnosis of 11beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. Oct 1979;49(4):546-51. [Medline].

  12. Van Vliet G, Polak M, Ritzén EM. Treating fetal thyroid and adrenal disorders through the mother. Nat Clin Pract Endocrinol Metab. Dec 2008;4(12):675-82. [Medline].

  13. German A, Suraiya S, Tenenbaum-Rakover Y, et al. Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab. Dec 2008;93(12):4707-10. [Medline].

  14. Mantero F, Opocher G, Rocco S. Long-term treatment of mineralocorticoid excess syndromes. Steroids. Jan 1995;60(1):81-6. [Medline].

  15. Burgu B, Duffy PG, Cuckow P, et al. Long-term outcome of vaginal reconstruction: comparing techniques and timing. J Pediatr Urol. Aug 2007;3(4):316-20. [Medline].

  16. Garner PR. Congenital adrenal hyperplasia in pregnancy. Semin Perinatol. Dec 1998;22(6):446-56. [Medline].

  17. Meyer-Bahlburg HF. What causes low rates of child-bearing in congenital adrenal hyperplasia?. J Clin Endocrinol Metab. Jun 1999;84(6):1844-7. [Medline]. [Full Text].

  18. Azziz R. Nonclassic adrenal hyperplasia. In: Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6th ed. St Louis, Mo: Mosby-Yearbook; 1997:175-8.

  19. Azziz R, Boots LR, Parker CR Jr. 11 beta-hydroxylase deficiency in hyperandrogenism. Fertil Steril. Apr 1991;55(4):733-41. [Medline].

  20. Cathelineau G, Brerault JL, Fiet J, et al. Adrenocortical 11 beta-hydroxylation defect in adult women with postmenarchial onset of symptoms. J Clin Endocrinol Metab. Aug 1980;51(2):287-91. [Medline].

  21. Deaton MA, Glorioso JE, McLean DB. Congenital adrenal hyperplasia: not really a zebra [published erratum appears in Am Fam Physician 1999 Sep 15;60(4):1107]. Am Fam Physician. Mar 1 1999;59(5):1190-6, 1172. [Medline]. [Full Text].

  22. Ghazi AA, Hadayegh F, Khakpour G, et al. Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia. J Endocrinol Invest. Jan 2003;26(1):84-7. [Medline].

  23. Kalaitzoglou G, New MI. Congenital adrenal hyperplasia. Molecular insights learned from patients. Receptor. Fall 1993;3(3):211-22. [Medline].

  24. Lucky AW, Rosenfield RL, McGuire J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab. May 1986;62(5):840-8. [Medline].

  25. Mantero F, Opocher G, Armanini D. 11 Beta-hydroxylase deficiency. J Endocrinol Invest. Jul-Aug 1995;18(7):545-9. [Medline].

  26. Merke DP, Tajima T, Chhabra A. Novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab. Jan 1998;83(1):270-3. [Medline]. [Full Text].

  27. Miller WL. Congenital adrenal hyperplasia in the adult patient. Adv Intern Med. 1999;44:155-73. [Medline].

  28. Miller WL. Early steps in androgen biosynthesis: from cholesterol to DHEA. Baillieres Clin Endocrinol Metab. Apr 1998;12(1):67-81. [Medline].

  29. Moran C, Knochenhauer ES, Azziz R. Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal. J Endocrinol Invest. Nov 1998;21(10):707-20. [Medline].

  30. New MI, Newfield RS. Congenital adrenal hyperplasia. In: Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6th ed. St Louis, Mo: Mosby-Yearbook; 1997:179-187.

  31. Pang S. Congenital adrenal hyperplasia. Baillieres Clin Obstet Gynaecol. Jun 1997;11(2):281-306. [Medline].

  32. Pang S, Levine LS, Lorenzen F. Hormonal studies in obligate heterozygotes and siblings of patients with 11 beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. Mar 1980;50(3):586-9. [Medline].

  33. Panitsa-Faflia C, Batrinos ML. Late-onset congenital adrenal hyperplasia. Ann N Y Acad Sci. Jun 17 1997;816:230-4. [Medline].

  34. Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Crit Rev Clin Lab Sci. Aug 1999;36(4):329-63. [Medline].

  35. White PC. Genetic diseases of steroid metabolism. Vitam Horm. 1994;49:131-95. [Medline].

  36. White PC. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am. Mar 2001;30(1):61-79, vi. [Medline].

  37. White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev. Aug 1994;15(4):421-38. [Medline].

  38. White PC, Obeid J, Agarwal AK. Genetic analysis of 11 beta-hydroxysteroid dehydrogenase. Steroids. Feb 1994;59(2):111-5. [Medline].

  39. White PC, Speiser PW. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am. Jun 1994;23(2):325-39. [Medline].

  40. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab. Feb 1983;56(2):222-9. [Medline].

Previous
Next
 
Steroidogenesis pathways in the adrenal cortex.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.